Top Medical Stocks To Own For 2018

One secretive virtual reality (VR) company will soon revolutionize how marijuana dispensaries operate.

The startup is currently developing an augmented reality (AR) headset that would allow medical marijuana patients to “touch” a marijuana bud without ever having to leave their couch.

Already, cannabis sales in North America are expected to increase 198%, from $6.7 billion in 2016, to over $20 billion by 2020.

And if these headsets make ordering marijuana easier, which would in turn increase sales, this technology will be another boon for marijuana dispensary stocks.

Top Medical Stocks To Own For 2018: SPDR S&P 500 ETF (SPY)

Advisors’ Opinion:

  • [By Shah Gilani]

    The first ETF in the U.S. was the SPDR S&P 500 ETF (NYSEArca:SPY). It was launched in 1993 by State Street Global Advisors under the product label Standard & Poor’s Depository Receipts (SPDRs).

  • [By Elizabeth Balboa]

    The SPDR Dow Jones Industrial Average ETF (NYSE: DIA) and the SPDR S&P 500 ETF Trust (NYSE: SPY) plunged 1.2 percent on the news, although it's worth noting that the markets had traded near these values Wednesday before riding a Thursday rally.


    For the details of SWISS RE LTD’s stock buys and sells, go to

    These are the top 5 holdings of SWISS RE LTDiShares Core S&P 500 (IVV) – 1,274,000 shares, 41.43% of the total portfolio. Shares added by 114.84%SPDR S&P 500 (SPY) – 1,192,350 shares, 38.52% of the total portfolio. Shares added by 158.64%iShares MSCI EAFE (EFA) – 1,043,001 shares, 8.7% of the total portfolio. Shares added by 12.39%iShares Floating Rate Bond (FLOT) – 1,000,000 shares, 7.33% of the total portfolio. NewStar Financial Inc (NEWS) – 3,000,000 shares, 4.01%

  • [By Wayne Duggan]

    As would be expected, the stock market tanked Tuesday, with the Dow Jones Industrial Average ETF (NYSE: DIA) down 2.2 percent and the SPDR S&P 500 ETF Trust (NYSE: SPY) down 1.7 percent in mid-day trading. The market leaders and laggards have been somewhat unexpected.

Top Medical Stocks To Own For 2018: SolarWindow Technologies, Inc. (WNDW)

Advisors’ Opinion:


    SolarWindow Technologies, Inc. (OTCQB:WNDW) is another third-party currently engaged in research and development to incorporate one of GLW’s glass products in an innovative manner. WNDW, a leading developer of transparent electricity-generating coatings for glass windows and flexible veneers, announced its plan to develop electricity-generating flexible glass. In particular, WNDW’s scientists and engineers recently applied layers of its liquid coatings onto GLW’s Willow Glass and laminated them under conditions that simulate the high pressure and temperatures of the manufacturing processes used by commercial glass and window producers. The result was a bendable glass “veneer” which generates electricity. WNDW anticipates installing these sheets of electricity-generating glass veneers over existing office tower windows, turning buildings into vertical power generators and helping decrease their carbon footprint. The company also believes that such veneers could be applied to flat and curved surfaces on automobiles, trucks, buses, airplanes, and boats to generate onboard electrical power. WNDW’s veneer products are being developed in collaboration with the U.S. Department of Energy’s National Renewable Energy Laboratory in an effort to commercialize WNDW’s products. While we saw no specific timeline for when WNDW would offer its products incorporating Willow Glass, we are once again excited by this innovative use of a GLW product.

Top Medical Stocks To Own For 2018: Freeport-McMoran, Inc.(FCX)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high options activity in Freeport-McMoRan Inc (NYSE: FCX). He said that traders were buying the January 13, 14-strike calls on Tuesday. He added that these calls expire prior to the earnings release and he is wondering if someone is betting that the company is going to pre-announce earnings results. Around 9,000 contracts were traded in the first half of the session and Jon Najarian decided to follow the trade. He is planning to hold the long position in Freeport-McMoRan for a week.


    Some energy stocks just cant seem to catch a break and Freeport-McMoRan Inc. (FCX) is one of those energy stocks. As we all know, FCX made some bad moves and decided to get into the oil business just as prices were peaking. That wouldnt be so bad, if it wasnt for the massive debt it took out to buy stakes in the gulf and other regions.

  • [By Ben Levisohn]

    Freeport-McMoRan (FCX) tumbled to the bottom of the S&P 500 today as the dollar rose and copper prices fell.

    Agence France-Presse/Getty Images

    Freeport-McMoRandropped 4.9% to $13.31 today, while the S&P 500 fell 0.6% to 2,381.92. The ICE U.S. Dollar Index rose 0.4% today, and
    Front Month Comex Copper for March delivery declined 1.7% to $2.6795 today.

    Axiom Capital’s Gordon Johnson warns that iron ore prices might be ready to drop:

    Beware: An Imminent End to an Epic Restock Suggests Iron Ore Prices May Snap Back Toward Fundamentals. Our work suggests ~70% of global iron ore demand can be met at a cash cost of <$23/t; add in $8/t for interest, CAPEX, & other, & we get to a breakeven of $31/t. In addition, w/ inventory restocking & current prices making further investment attractive, despite current excesses, we believe iron ore prices should be ~$40/t (i.e., below marginal costs); in this fashion, w/ Chinese real estate investment on the decline, we view iron ore spot prices >$62/t as a stretch. So what has been propping prices? In our view, one word restocking; first by the mills, undergoing the biggest restocking effort of Chinese steel in >6-yrs., & then by the traders, which have built their iron ore port stocks to a record, w/ days of inventory at a 2.5-yr. high (Ex. 18-19). Yet, w/ data pointing to peak steel inventory, implying risk to n-term ore demand, & the govt probing speculative trading, we see the current restocking cycle as very much so in the later innings

    Freeport-McMoRan’s market capitalization fell to $19.2 billion today from $20.2 billion yesterday. It reported a net loss of $4 billion on sales of $14.8 billion in 2016.

  • [By Reuben Gregg Brewer]

    Freeport-McMoRan Inc. (NYSE:FCX) and Barrick Gold (NYSE:ABX) rank among the largest gold and copper miners in the world. After years of retrenching, both are in better operational and financial shape than they were when commodity prices started to tumble in 2011. But now that metals prices are finally rising, there are new troubles to face. Barrick’s headwinds, however, don’t look nearly as formidable as what Freeport-McMoRan is facing.

  • [By Benzinga News Desk]

    Stephens (Equal-Weight) and Citi (Sell) both downgraded Atwood Oceanics (NYSE: ATW).

    Sell-Side's Most Noteworthy Calls
    Investec downgraded Anheuser-Busch (NYSE: BUD) to Hold.
    Deutsche Bank downgraded Freeport McMoRan (NYSE: FCX) to Hold.
    Goldman Sachs upgraded Microsoft (NASDAQ: MSFT) to Buy.
    Barclays upgraded Teck Resources (NYSE: TCK) to Overweight.
    BTIG started Adobe (NASDAQ: ADBE) at Neutral.
    Deal Talk

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Freeport-McMoran Inc. (NYSE: FCX) which traded down about 14.5% at $16.08. The stocks 52-week range is $11.05 to $20.25. Volume was 77.5 million compared to the daily average volume of 17.7 million.

Top Medical Stocks To Own For 2018: Kalytera Therapeutics, Inc. (QUEZF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Kalytera Therapeutics Inc (OTC: QUEZF) closed a C$13.4 million ($10.2 million) tranche of a private placement for the acquisition of Talent Biotechs Ltd.

Top Medical Stocks To Own For 2018: Anavex Life Sciences Corp.(AVXL)

Advisors’ Opinion:


    Anavex Life Sciences (OTCQX:AVXL) is down ~40% since Amit Ghate said it would trade substantially lower in an interview with the PRO Weekly Digest in June (see his update comment).


    The lead drug from Anavex Life Sciences (AVXL) — called Anavex 2-73 — has just reported very promising phase 2a results in Alzheimer’s patients at the annual CTAD conference.

Top Medical Stocks To Own For 2018: Inc.(SOHU)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Sogou is Baidu’s biggest rival when it comes to mobile search engine market share. The app is owned by Inc (NASDAQ: SOHU), and its position as second fiddle to Baidu makes it most similar to Microsoft Corporation (NASDAQ: MSFT)’s Bing.

  • [By Lisa Levin] (NASDAQ: SOHU) shares rose 2.77% to touch a new 52-week high of $71.54. Analysts at Goldman Sachs upgraded the stock from neutral to conviction buy.

  • [By Lisa Levin] Inc (NASDAQ: SOHU) shares were also up, gaining 14 percent to $57.89. reported a Q2 loss of $1.85 per share on revenue of $461.168 million.